{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T20:09:56Z","timestamp":1699301396497},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.2169\/internalmedicine.3824-19","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T22:04:17Z","timestamp":1575583457000},"page":"941-944","source":"Crossref","is-referenced-by-count":3,"title":["Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection"],"prefix":"10.2169","volume":"59","author":[{"given":"Kazuki","family":"Ohya","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Morio","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol 53: 557-565, 2018.","DOI":"10.1007\/s00535-017-1391-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Morio K, Imamura M, Kawakami Y, et al. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. J Gastroenterol Hepatol 32: 645-650, 2017.","DOI":"10.1111\/jgh.13511"},{"key":"3","unstructured":"3. El-Guindi MA. Hepatitis C viral infection in children: updated review. Pediatr Gastroenterol Hepatol Nutr 19: 83-95, 2016."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schwarz KB, Molleston JP, Jonas MM, et al. Durability of response in children treated with pegylated interferon alfa-2a \u00b1 ribavirin for chronic hepatitis C. J Pediatr Gastroenterol Nutr 62: 93-96, 2016.","DOI":"10.1097\/MPG.0000000000000929"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 56: 523-531, 2012.","DOI":"10.1002\/hep.25690"},{"key":"6","unstructured":"6. Yang CHT, Yoo ER, Ahmed A. The role of direct-acting antivirals in the treatment of children with chronic hepatitis C. J Clin Transl Hepatol 5: 59-66, 2017."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tsunoda T, Inui A, Kawamoto M, et al. Effects of pegylated interferon-\u03b1-2a monotherapy on growth in Japanese children with chronic hepatitis C. Hepatol Res 44: 251-258, 2014.","DOI":"10.1111\/hepr.12118"},{"key":"8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"8. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61: 77-87, 2015.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pawlowska M, Domagalski K, Pniewska A, et al. What's new in hepatitis C virus infections in children? World J Gastroenterol 21: 10783-10789, 2015.","DOI":"10.3748\/wjg.v21.i38.10783"},{"key":"10","unstructured":"10. Yeung CY, Lee HC, Chan WT, et al. Vertical transmission of hepatitis C virus: current knowledge and perspectives. World J Hepatol 6: 643-651, 2014."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Garazzino S, Calitri C, Versace A, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 173: 1025-1031, 2014.","DOI":"10.1007\/s00431-014-2286-6"},{"key":"12","unstructured":"12. Mizuochi T, Takano T, Yanagi T, et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol 53: 419-426, 2018."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Toyoda H, Kumada T, Takaguchi K, et al. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 142: 2624-2628, 2014.","DOI":"10.1017\/S0950268814000478"},{"key":"14","unstructured":"14. Suzuki M, Tajiri H, Tanaka Y, et al. Peginterferon therapy in children with chronic hepatitis C: a nationwide, multicenter study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr 63: 88-93, 2016."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr 28: 93-100, 2016.","DOI":"10.1097\/MOP.0000000000000313"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 66: 371-378, 2017.","DOI":"10.1002\/hep.28995"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 66: 1102-1110, 2017.","DOI":"10.1002\/hep.29278"},{"key":"18","unstructured":"18. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). HCV in Children [Internet]. [cited 2018 Jul 2]. Available from: https:\/\/www.HCVGuidance.org"},{"key":"19","unstructured":"19. Lagging M, Wejst\u00e5l R, Duberg AS, et al. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infect Dis (Lond) 50: 569-583, 2018."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 61: S58-S68, 2014.","DOI":"10.1016\/j.jhep.2014.07.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Honda K, Seike M, Oribe J, et al. Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. Hepatol Res 48: 255-263, 2018.","DOI":"10.1111\/hepr.12994"},{"key":"22","unstructured":"22. Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA Study. Hepatology. Forthcoming."},{"key":"23","unstructured":"23. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61: 1798-1808, 2015."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/7\/59_3824-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T03:51:30Z","timestamp":1585972290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/7\/59_3824-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3824-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}